Business Wire

UAE Begins Mapping Air Corridors for Air Taxis and Cargo Drones to Transform Urban Transportation

13.2.2025 18:12:00 CET | Business Wire | Press release

Share

Initial advanced air mobility (AAM) regulations under development for the UAE GCAA and ATRC entities – TII and ASPIRE collaborate on technical expertise and airspace management

The UAE has taken a bold step towards redefining urban transportation with the commencement of air corridor mapping and regulatory framework development for piloted and autonomous air taxis and cargo drones. This transformative initiative marks a major leap forward in the nation’s mission to lead the future of mobility. Through a strategic partnership between the General Civil Aviation Authority (GCAA) and the Advanced Technology Research Council (ATRC) entities—Technology Innovation Institute (TII) and ASPIRE—the UAE is on track to reshape the way people and goods move through urban spaces.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213996930/en/

UAE Begins Mapping Air Corridors for Air Taxis and Cargo Drones to Transform Urban Transportation (Photo: AETOSWire)

With aerial corridors and regulations set to be defined within the next 20 months, this pioneering effort demonstrates the UAE’s unwavering commitment to deploying safe, advanced, sustainable transportation solutions that will not only ease congestion but also set a global benchmark for future urban mobility systems. These routes will connect key international airports and iconic places in the UAE, extending further to ensure seamless integration of piloted and autonomous air taxis and cargo drones across the nation’s urban landscapes.

His Excellency Saif Mohammed Al Suwaidi, Director General of the GCAA said: “Air corridor mapping for piloted and autonomous air taxis and drones is a crucial milestone that will enable the seamless implementation of Advanced Air Mobility into the UAE’s infrastructure. This initiative ensures the safe and efficient adoption of air mobility, delivering transformative solutions to urban transport and paving the way for a smarter, more connected future.”

The UAE’s forward-thinking approach to urban transportation will be supported by TII’s expertise in airspace management, ensuring the safe integration of piloted and autonomous air taxis and cargo drones into urban environments. These new air corridors will offer innovative solutions for passenger and cargo transport, relieving pressure on traditional road networks and improving connectivity.

Dr. Najwa Aaraj, CEO of TII, said: “This transformative collaboration with GCAA is reshaping the future of urban transportation. By advancing airspace management and integrating piloted and autonomous air taxis and cargo drones, we are not only enhancing urban connectivity but also driving sustainable and accessible mobility solutions that will benefit future generations.”

Stephane Timpano from ASPIRE said: “Addressing real-time urban mobility challenges through innovative solutions like air taxis and drones is a major step forward. This initiative directly supports sustainable economic growth by creating a flexible and diverse transport system that eases pressure on urban infrastructure and fosters smarter, more resilient cities.”

The agreement was announced during World Governments Summit 2025.

Advanced Air Mobility (AAM) refers to the use of automated aircraft in urban and suburban settings to deliver innovative transport solutions for people and goods. With TII at the helm of developing the technical aspects of AAM and ASPIRE focusing on creating a network of stakeholders, including regulators, industry leaders, and researchers, this collaboration aims to establish a comprehensive regulatory framework that ensures safety and operational efficiency.

Prof. Enrico Natalizio, Chief Researcher of the Autonomous Robotics Research Center at TII, commented: “At TII, we’re developing advanced AI-powered control, vision and communication algorithms for autonomous systems that enable real-time decision-making for air taxis and drones. Having mastered this technology, we are able to propose methodologies for AAM corridors design to optimize routes, ensure collision avoidance, and integrate seamlessly with urban airspace, marking a key step toward efficient and safe autonomous air mobility in complex urban environments.”

Together with GCAA, these entities will define the airspace regulations and develop airspace management systems, making the UAE a global benchmark for advanced urban mobility.

*Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20250213996930/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye